Table 44Hierarchy of evidence, KQ5, head and neck cancer

Level of EvidenceStudynSettingTreatmentsOutcomeResults
RCT stratified on HER2 status/HER2-guided vs. non-HER2-guided
RCT prespecified MV SGA
RCT post-hoc MV SGA
RCT treatment by HER2 SGA
1-arm prespecified MV analysis
1-arm post-hoc MV analysis
1-arm UV analysisNagler 200336malignant
salivary
tumors
surgeryOSIHC HER2+ vs. - p=.0004
Khan 200277SCC or oral cavity or oropharynxsurgery + EBRTDFS IHC HER2+ vs. - RR=0.83 (95% CI: 0.29–2.4)
OSIHC HER2+ vs. - RR=1.4 (95% CI: 0.62–3.3)
OSFISH HER2+ vs. - p=.15

Abbreviations: DFS: disease-free survival; EBRT: external-beam radiation therapy; MV: multivariate; OS: overall survival; SCC: squamous-cell carcinoma; SGA: subgroup analysis; UV: univariate;

From: 3, Results and Conclusions

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.